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Background—The role of inflammatory markers is not well defined for either diagnosis or treatment of pericarditis. The
aim of this study is to prospectively evaluate the frequency of high-sensitivity C-reactive protein (hs-CRP) elevation in
patients with acute pericarditis, its time course of normalization, and the possible importance for diagnosis, therapy,
and prognosis.
Methods and Results—Two hundred consecutive patients with viral or idiopathic acute pericarditis (mean age,
5315.5 years; 103 men) were studied from August 2005 to August 2007 in 2 Italian referral centers. Hs-CRP was
determined at presentation and then every week until normalization. Hs-CRP elevation was recorded in 156 of 200
cases (78%) at presentation. Recognized causes of a negative hs-CRP at presentation were early assessment in 15
of 44 cases (34%) and previous anti-inflammatory therapies in 22 of 44 cases (50%). Hs-CRP normalization was
achieved with the following time course: 120 of 200 (60%) at week 1, 170 of 200 (85%) at week 2, 190 of 200
(95%) at week 3, and all cases (100%) at week 4. In multivariable analysis, incomplete response to empirical
anti-inflammatory therapy at week 1 (hazard ratio, 2.98; 95% confidence interval, 1.80 to 4.94; P0.001),
corticosteroid therapy (hazard ratio, 2.80; 95% confidence interval, 1.59 to 4.95; P0.001), and the presence of
elevated hs-CRP at week 1 (hazard ratio, 2.36; 95% confidence interval, 1.32 to 4.21; P0.004) were independent
risk factors for recurrence.
Conclusions—Hs-CRP is elevated at the initial presentation in 3 of 4 cases of acute pericarditis, identifies patients at higher
risk of recurrence, and could be used to monitor disease activity and select appropriate therapy length. (Circulation. 2011;
123:1092-1097.)
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There are no universally accepted criteria for the diagnosisof pericarditis. In clinical practice, some criteria are
usually adopted (chest pain, pericardial rubs, PR depression
and diffuse ST-segment elevation on ECG, pericardial effu-
sion; at least 2 of 4 should be present for the diagnosis), and
the role of inflammatory markers (eg, C-reactive protein
[CRP]) is not well defined.1–5
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Pericarditis is an inflammatory disease, and evidence of
elevated markers of inflammation could support the diagno-
sis. Moreover, the same length of therapy is empirical, and
markers of inflammation (ie, CRP) may be a useful guide for
treatment because it can be assumed that anti-inflammatory
therapy should be continued until the inflammation is extin-
guished. On this basis, persistent elevation of inflammatory
markers, as evidence of disease activity, could be associated
with a worse prognosis.
The aim of the present study is to prospectively evaluate
the frequency of high-sensitivity CRP (hs-CRP) elevation in
patients with acute pericarditis, its time course of normaliza-
tion, and the possible importance for diagnosis, therapy, and
prognosis.
Methods
Patients
All consecutive cases of acute pericarditis within 24 hours from
symptom onset were screened for inclusion in a prospective
cohort study from August 2005 to August 2007. A final diagnosis
of idiopathic or viral acute pericarditis was reached at the end of
the diagnostic assessment, which included chest x-ray, echocar-
diography, viral serology, and other specific testing according to
the initial clinical presentation. Pericardiocentesis was done when
a bacterial or neoplastic etiology was suspected or in case of
cardiac tamponade or severe pericardial effusion without re-
sponse to medical therapy after 1 week. Patients with a final
diagnosis of viral and idiopathic pericarditis were included in the
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present study. A flow diagram of the screened and included
population is shown in Figure 1. The diagnosis of acute pericar-
ditis was done according to available published criteria.1– 8
Diagnostic criteria included pericarditic typical chest pain, peri-
cardial friction rubs, widespread ST-segment elevation or PR
depressions not reported previously, and new or worsening
pericardial effusion. A clinical diagnosis of acute pericarditis was
made when at least 2 of these criteria were present. Criteria for
the diagnosis of recurrence included recurrent pain and 1 or more
of the following signs: fever, pericardial friction rub, ECG
changes, echocardiographic evidence of pericardial effusion, and
an elevation in the white blood cell count, erythrocyte sedimen-
tation rate, or CRP.4 –9 During follow-up, the presence or absence
of the aforementioned criteria for recurrence was adopted for the
definition of recurrence-free survival.
Hs-CRP Assessment
Hs-CRP was determined with the use of an enhanced turbidime-
tric immunoassay technique (Siemens Healthcare Diagnostics).
Testing was done at presentation and then every week until
normalization. In healthy young adult volunteer blood donors, the
median concentration of CRP is 0.8 mg/L, the 90th centile is 3.0
mg/L, and the 99th centile is 10 mg/L. In unselected general
populations of ostensibly healthy subjects, the median CRP value
is slightly higher than among blood donors and tends to increase
with age, presumably reflecting the increasing incidence of
subclinical pathologies. Hs-CRP was considered elevated at a
hs-CRP concentration 3.0 mg/L, according to the reference
interval for the test employed. De novo hepatic synthesis starts
very rapidly after a single stimulus, with serum concentrations
rising to 3.0 to 5.0 mg/L by 6 hours and peaking at 48
hours, and therefore it is possible that an early presentation might
influence the observed values of CRP.10
Medical Therapy
Empirical anti-inflammatory therapy was prescribed to all patients
with an attack dose for 7 days (favoring the use of aspirin or a
nonsteroidal anti-inflammatory drug over corticosteroids) and then
tapering within 3 to 4 weeks.
Specific anti-inflammatory attack doses were as follows: aspirin
750 to 1000 mg every 8 hours, ibuprofen 600 mg every 8 hours, or
indomethacin 50 mg every 8 hours. Colchicine was added according
to the treating physician’s discretion at the dose of 0.5 mg twice daily
for patients weighing 70 kg for 3 months (0.5 mg once daily for
patients weighing 70 kg). Prednisone was used at the attack dose
of 0.2 to 0.5 mg/kg per day and then followed by gradual tapering
over months.
Follow-Up
Persistence of symptoms at 1 week of therapy, recurrences, cardiac
tamponade, and constrictive pericarditis were considered adverse
events during follow-up.
An incomplete response to therapy was considered the persistence
of symptoms with evidence of disease activity (fever without
alternative causes, pericardial rubs, new or worsening ECG changes,
elevated hs-CRP, and appearance or worsening of pericardial effu-
sion) without a free interval, whereas recurrence was considered a
situation in which a new attack occurred after a period of complete
disappearance of symptoms and CRP normalization if previously
elevated.6,7,9
Follow-up data were collected after clinical visits and after ECGs
and echocardiograms were performed.
Statistical Analysis
Continuous data were reported as meanSD and compared with the
Mann-Whitney test. Categorical variables were expressed as propor-
tions or percentages and compared with the 2 test. Time-to-event
distributions were estimated by the Kaplan-Meier method and
compared with the log-rank test. The Cox proportional hazards
model was used to identify independent risk factors for recurrences.
A stepwise selection procedure was adopted. A P value of 0.05
was considered to show statistical significance and was adopted as
the significance level for variable entry and stay for stepwise
selection. Statistical analysis was performed with the use of SPSS
13.0 software (Chicago, IL).
The authors had full access to and take responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Baseline Features
A total of 200 patients aged 18 to 90 years (mean age,
5315.5 years; 103 men) were included in the study period.
Hs-CRP was normal in 44 cases (22%) and elevated in 156 of
200 study patients (78%) at presentation. Identified causes of
initial negative results were as follows: (1) early assessment
in 15 of 44 cases (34%) because hs-CRP became positive at
a second determination within 24 to 48 hours and (2) use of
previous empirical anti-inflammatory therapy in 22 of 44
cases (50%). Therefore, only 7 of 200 patients (3.5%) had a
persistently normal hs-CRP with no previous treatment.
Baseline data including diagnostic criteria for acute pericar-
ditis in patients with or without hs-CRP elevation are reported
in Table 1.
Elevated hs-CRP was recorded in 31 of 40 patients (77.5%)
with a specific etiology (Figure 2).
Follow-Up Data
A nonelevated hs-CRP was found in 120 of 200 patients
(60%) at week 1, 170 of 200 patients (85%) at week 2, 190 of
200 patients (95%) at week 3, and all cases (100%) at week
4 (Figure 3). Normalization was achieved within 2 weeks in
most cases, and normalization was achieved at 1 month in all
cases. Patients with persistent elevation of hs-CRP after 1
week of therapy had a shorter recurrence-free survival (Fig-
ure 4). All patients were analyzed for outcomes, and no
patient was lost at follow-up.
After a mean follow-up of 24 months, the following
adverse events were noted: persistence of symptoms and
incomplete response to anti-inflammatory therapy at week 1
were recorded in 66 cases (33%), recurrences in 70 cases
(35%), and cardiac tamponade in 4 cases (2%). No cases of
constrictive pericarditis were recorded.
In multivariable analysis (including age, gender, peri-
cardial effusion, elevated hs-CRP at presentation, cortico-
Figure 1. Flow diagram of the studied population with acute
pericarditis (autoimmune etiologies included pericardial injury
syndromes and connective tissue diseases).
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steroid use, incomplete response to therapy at week 1, and
elevated hs-CRP at week 1), incomplete response to
empirical anti-inflammatory therapy at week 1 (hazard
ratio, 2.98; 95% confidence interval, 1.80 to 4.94;
P0.001), corticosteroid therapy (hazard ratio, 2.80; 95%
confidence interval, 1.59 to 4.95; P0.001), and the
presence of elevated hs-CRP at week 1 (hazard ratio, 2.36;
95% confidence interval, 1.32 to 4.21; P0.004) were
independent risk factors for recurrences considered as
major adverse events during follow-up (Table 2).
Discussion
The use of elevated markers of inflammation has been
recommended for diagnostic purposes by the 2004 Euro-
Table 1. Comparison of Baseline Clinical Characteristics of
Patients With or Without High-Sensitivity C-Reactive Protein
Elevation at Presentation
Characteristic
High-Sensitivity C-Reactive
Protein
P
(3.0 mg/L)
(n 44)
(3.0 mg/L)
(n 156)
Mean age, y 5216 5314 0.686
Female gender (n97) 22 (50.0) 75 (48.1) 0.959
Pericarditic chest pain
(n200)
44 (100.0) 156 (100.0) 0.999
Pericardial rub (n66) 14 (31.8) 52 (33.3) 0.996
Diagnostic ECG changes*
(n170)
37 (84.1) 133 (85.3) 0.966
New or worsening pericardial
effusion (n90)
19 (43.2) 71 (45.5) 0.921
Fulfilled diagnostic criteria
2 of 4 44 (100.0) 156 (100.0) 0.999
3 of 4 36 (81.8) 130 (83.3) 0.993
4 of 4 20 (45.5) 72 (46.2) 0.929
Aspirin or NSAID (n170) 37 (84.1) 133 (85.3) 0.966
Corticosteroid therapy
(n30)
7 (15.9) 23 (14.7) 0.966
Colchicine (n100) 21 (47.7) 79 (50.6) 0.866
Values in parentheses are percentages. NSAID indicates nonsteroidal
anti-inflammatory drug.
*Widespread ST-segment elevation or PR depressions.
Figure 2. High-sensitivity C-reactive protein
(hs-CRP) elevation at presentation in patients with
acute pericarditis and a nonviral, nonidiopathic
etiology.
Figure 3. High-sensitivity C-reactive protein (CRP) elevation at
presentation and its time course of normalization in patients
with idiopathic or viral acute pericarditis (weekly assessment).
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pean guidelines on the management of pericardial diseases.11
However, the role of elevated markers of inflammation (ie,
CRP) is not well defined. Currently adopted diagnostic
criteria are mainly clinical and are based on symptoms
(pericarditic chest pain), signs (pericardial rubs), or instru-
mental findings (widespread ST-segment elevation, pericar-
dial effusion) and do not include markers of inflammation.
Nevertheless, pericarditis is generally an intense inflamma-
tory disease, and elevation of such markers could be useful to
confirm the diagnosis. Moreover, the treatment of pericarditis
is empirical for either the choice of drugs or length of therapy
and is expected to extinguish the inflammation. CRP could be
used as a diagnostic marker and also to monitor the disease
activity and the appropriate length of therapy.5,12
CRP is one of the “acute phase” proteins, the serum or
plasma levels of which rise during a general, unspecific
response to infectious and noninfectious inflammatory
processes. Because elevated CRP values are always asso-
ciated with pathological changes, the CRP assay may
provide useful information for the diagnosis, therapy, and
monitoring of inflammatory processes such as acute
pericarditis.
Plasma CRP is produced only by hepatocytes, predomi-
nantly under transcriptional control by the cytokine
interleukin-6. De novo hepatic synthesis starts very rapidly
after a single stimulus, with serum concentrations rising to
5 mg/L by6 hours and peaking at48 hours. The plasma
half-life of CRP is 19 hours and is constant under all
conditions of health and disease, so that the sole determinant
of circulating CRP concentration is the synthesis rate, which
thus directly reflects the intensity of the pathological pro-
cesses stimulating CRP production. When the stimulus for
increased production ceases completely, the circulating CRP
concentration falls rapidly, at almost the rate of plasma CRP
clearance.10
At present, the frequency of hs-CRP elevation is unknown
in pericarditis as well as the time course of its normalization
and the possible prognostic significance.
In this prospective study, we demonstrated an elevation
of hs-CRP in 3 of 4 cases at presentation; thus, hs-CRP
Figure 4. Recurrence-free survival in
patients with (dotted line) or without (thick
line) high-sensitivity C-reactive protein (hs-
CRP) elevation at week 1. Differences of
event-free survivals are evident after 2
months and increase in the first 12 months.
Table 2. Hazard Ratios for Recurrence in the Cox Proportional
Hazards Model
Risk Factor Hazard Ratio
95% Confidence
Interval P
Incomplete response to
therapy at week 1 2.98 1.80–4.94 0.001
Corticosteroid therapy 2.80 1.59–4.95 0.001
Elevated hs-CRP at
week 1 2.36 1.32–4.21 0.004
hs-CRP indicates high-sensitivity C-reactive protein.
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elevation at presentation is common but not present in all
cases. In some patients, hs-CRP was initially normal but
increased later. A diagnosis of pericarditis should rely on
clinical criteria and not only on CRP elevation, although it
may support the clinical suspicion. In patients with peri-
carditis, common causes of normal hs-CRP at presentation
may include previous empirical anti-inflammatory therapy
(50% of cases) and an early assessment without serial
testing of hs-CRP (approximately one third of the initially
negative cases). On this basis, if pericarditis is suspected,
repeated testing for hs-CRP is indicated with an initial
negative finding, and the possible role of recent empirical
anti-inflammatory drugs should also be considered. An
alternative cause to be considered is also the presence of
myocardial involvement because hs-CRP may be normal in
myocarditis.13,14 Overall, we found only 7 of 200 patients
(3.5%) with a persistently negative hs-CRP in the absence
of previous anti-inflammatory treatments. This finding is
important in the clinical setting because an initial negative
hs-CRP does not rule out pericarditis.
Data from the overall group of patients with acute
pericarditis (Figures 1 through 3) show that elevation of
hs-CRP at presentation is equally distributed in patients
with or without a specific etiology, although elevation of
hs-CRP is more common in patients without a neoplastic
cause (Figure 2).
Hs-CRP elevation, when available, is especially valu-
able to guide the length of therapy. Most cases of pericar-
ditis show a normalization of hs-CRP within 2 weeks, but
persistent elevation of hs-CRP at week 1 may indicate
ongoing inflammation and requires prolonged therapies.
Common recommended therapeutic dosing includes 1 to 2
weeks of empirical therapy. However, at the end of the
first week, only 60% of patients had a normal hs-CRP test,
and thus the attack dose of anti-inflammatory therapy
should be continued until the end of the second week in
40% of cases and for an even longer time if hs-CRP is
still elevated at week 2, as occurred in 15% of cases in this
study. Dosing and serial monitoring of CRP until normal-
ization seem warranted to prevent the early withdrawal of
the attack dose. On this basis, appropriate weekly moni-
toring of CRP may be useful to follow the disease activity
and guide the appropriate length of therapy, with contin-
uation of the attack doses until CRP normalization, at
which time tapering may be considered. Persistent eleva-
tion of CRP should be considered a risk factor for
recurrence, as well as other recognized factors such as
corticosteroids15–19 and incomplete response to medical
therapy.19,20
The main conclusions of the study are as follows: (1)
hs-CRP is elevated at the initial presentation in 3 of 4 cases
of acute pericarditis, and thus a normal value of hs-CRP at
presentation does not exclude the diagnosis but may confirm
the clinical suspicion; (2) persistently elevated hs-CRP may
identify patients at higher risk of recurrence; (3) for patients
with elevated hs-CRP, the attack dose of anti-inflammatory
therapy should be continued until hs-CRP normalization
instead of an empirical therapy length; and (4) in some
patients, hs-CRP, although normal at presentation, may in-
crease within the first week, and thus appropriate serial
testing for hs-CRP should be planned for patients with an
initial negative result.
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CLINICAL PERSPECTIVE
Pericarditis is an inflammatory disease, and evidence of elevated markers of inflammation could support the diagnosis.
Unfortunately, the appropriate length of therapy is unknown, and drugs are administered empirically. Nevertheless,
markers of inflammation (ie, C-reactive protein [CRP]) may be a useful guide for treatment because it can be assumed that
anti-inflammatory therapy should be continued until the inflammation is extinguished. On this basis, persistent elevation
of inflammatory markers, as evidence of disease activity, could be associated with a worse prognosis. No prospective study
has evaluated the prevalence and clinical meaning of CRP for diagnosis, therapy, and prognosis in acute pericarditis. The
main conclusions of the study are as follows: (1) high-sensitivity CRP (hs-CRP) is elevated at the initial presentation in
3 of 4 cases of acute pericarditis, and thus a normal value of hs-CRP at presentation does not exclude the diagnosis but
may confirm the clinical suspicion; (2) persistently elevated hs-CRP may identify patients at higher risk of recurrence; (3)
for patients with elevated hs-CRP, the attack dose of anti-inflammatory therapy should be continued until hs-CRP
normalization instead of an empirical therapy length, as is commonly done in clinical practice; and (4) in some patients,
hs-CRP is normal at presentation but may increase within the first week, and thus appropriate serial testing for hs-CRP
should be planned for patients with an initial negative result. Hs-CRP is elevated at the initial presentation in3 of 4 cases
of acute pericarditis, identifies patients at higher risk of recurrence, and could be used to monitor disease activity and select
appropriate therapy length.
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